Tryptophan metabolites in serum and feces of patients with non-small cell lung cancer
E. Yu. Zlatnik,
A. B. Sagakyants,
O. P. Shatova,
A. A. Zabolotneva,
S. A. Appolonova,
N. E. Moskaleva,
I. O. Meshkov,
S. A. Rumyantsev,
A. V. Shestopalov https://doi.org/10.25789/YMJ.2021.76.22
Abstract
Our aim is to study the content of tryptophan metabolites in blood serum and feces in patients with NSCLC for further estimation of possible correction of microbiomes` functional state and its role in the providence of the efficiency of treatment. The levels of tryptophan metabolites in blood serum and feces of 100 patients with NSCLC in comparison with 100 healthy donors were studied. A number of differences were obtained: in serum of patients a statistically significant decrease in the levels of tryptophan, its` dominant metabolites of microbiotic origin - tryptamine, serotonin, downtrend for xanthurenic acid along with an increase of the levels of quinolinic acid (in tendency). In feces the levels of indole in patients had an uptrend in comparison with donors. We consider that the decrease of tryptophan and its` dominant metabolites in serum of patients with NSCLC may be due to the utilization of tryptophan by tumor cells.
Supporting agencies: The study was carried out within the framework of research work under the contract 0373100122121000031 for the implementation of research work under the project «Study of the IDO1 / TDO2-KYN-AhR system in the host-microbiota-tumor system in malignant neoplasms in order to develop a prodrug for their treatment», dated 01.06 .2021 with the Federal State Budgetary Institution «CSP» of the FMBA of Russia.
About the Authors
E. Yu. Zlatnik
National Medical Research Centre for Oncology
Russian Federation
Russian Federation
Zlatnik Elena Yurievna, MD – professor, chief researcher of laboratory of immunophenotyping of tumors
A. B. Sagakyants
National Medical Research Centre for Oncology
Russian Federation
Russian Federation
Sagakyants Alexander Borisovich – associate professor, PhD, head of laboratory of tumor immunophenotyping
Researcher ID (WOS): M-8378-2019. Author ID (Scopus): 24329773900
O. P. Shatova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Shatova Olga Petrovna – associate professor, PHD, Department of Biochemistry and Molecular
AuthorID: 786647
A. A. Zabolotneva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Zabolotneva Anastasia Alexandrovna – PhD, associate professor, Department of Biochemistry and Molecular
S. A. Appolonova
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Appolonova Svetlana Alexandrovna – Candidate of Chemical Sciences, head of the Laboratory
AuthorID: 153451
N. E. Moskaleva
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Russian Federation
Moskaleva Natalia Evgenievna – Candidate of Biological Sciences, leading researcher
AuthorID: 152176
I. O. Meshkov
Centre for Strategic Planning of FMBA of Russia
Russian Federation
Russian Federation
Meshkov Ivan Olegovich – analyst of the Department of Analysis and Forecasting of Biomedical health risks
S. A. Rumyantsev
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Rumyantsev Sergey Alexandrovich – Department of Biochemistry and Molecular Biology
AuthorID: 216741
A. V. Shestopalov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Shestolapov Alexander Vyacheslavovich – MD, professor, head of the department, Department of Biochemistry and Molecular Biology
AuthorID: 92580
References
1. Kit OI. Molecular genetic and phenotypic characteristics of patients with lung adenocarcinoma among inhabitants of the south of russia / Kit OI, Vodolazhsky DI, Maksimov AYu, Lazutin YuN [at al.] // Molecular medicine. - 2016. - Vol. 14, № 6. - P. 35-40.
2. Coupling features of intestinal and serum indole pools in obesity/ Shestopalov A.V., Shatova O.P., Zabolotneva A.A., Gaponov A.M., Moskaleva N.E., Appolonova S.A., Makarov V.V., Yudin S.M., Rumyantsev A.G., Roumiantsev S.A. // Problems of Biological, Medical and Pharmaceutical Chemistry. - 2021.- Т. 24, N 10. - С. 3-12. Doi: 10.29296/25877313-2021-10-01.
3. Heyes MP. Quinolinic acid and inflammation // Ann N Y Acad Sci. 1993. - Vol. 679. - 211-6. Doi: 10.1111/j.1749-6632.1993.tb18300.x
4. Hsu YL. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis / YL Hsu, JY Hung, SY Chiang [et al.] // Oncotarget. – 2016. – Vol. 7, № 19. – P. 27584-98. Doi: 10.18632/oncotarget.8488
5. Kasper SH. Chemical inhibition of kynureninase reduces pseudomonas aeruginosa quorum sensing and virulence factor expression / SH Kasper, RP Bonocora, JT Wade [et al.] // ACS Chem. Biol. – 2016. – Vol. 11, № 4. – P. 1106–1117. Doi: 10.1021/acschembio.5b01082
6. Kennedy PJ. Kynurenine pathway metabolism and the microbiota-gut-brain axis / PJ Kennedy, JF Cryan, TG Dinan [et al.] // Neuropharmacology. 2017; 112:399e412. Doi: 10.1016/j.neuropharm.2016.07.002
7. Lamas B. Aryl hydrocarbon receptor and intestinal immunity / B Lamas, JM Natividad, H Sokol // Mucosal Immunology. – 2018. – Vol. 11, № 4. – P. 1024-38. Doi: 10.1038/s41385-018-0019-2
8. Lamas B. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligand / B Lamas, ML Richard, V Leducq [et al.] // Nature medicine. – 2016. – Vol. 22, № 6. – P. 598-605. Doi: 10.1038/nm.4102
9. Lanser L. Inflammation-induced tryptophan breakdown is related with anemia, fatigue, and depression in cancer / L Lanser, P Kink, EM Egger [et al.] // Front Immunol. – 2020. – Vol. 11. – P. 249. Doi: 10.3389/fimmu.2020.00249
10. Lugo-Huitrón R. Quinolinic acid: an endogenous neurotoxin with multiple targets / R Lugo-Huitrón, P Ugalde Muñiz, B Pineda [et al.] // Oxid Med Cell Longev. – 2013. – Vol. 2013. – P. 104024. Doi: 10.1155/2013/104024
11. Mandarano M. Kynurenine/tryptophan ratio as a potential blood-based biomarker in non-small cell lung cancer / M Mandarano, E Orecchini, G Bellezza [et al.] // Int J Mol Sci. – 2021. – Vol. 22, № 9. – P. 403. Doi: 10.3390/ijms22094403
12. Ninomiya S. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs / S Ninomiya, N Narala, L Huye [et al.] // Blood. – 2015. – Vol. 125, № 25. – P. 3905-16. Doi: 10.1182/blood-2015-01-621474
13. Onesti CE. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy / CE Onesti, F Boemer, C Josse [et al.] // J Transl Med. – 2019. Vol. 17, № 1. – P. 239. Doi: 10.1186/s12967-019-1984-2
14. Schiering C. Feedback control of AHR signaling regulates intestinal immunity / C Schiering, E Wincent, A Metidji [et al.] // Nature. – 2017. Vol. 542, № 7640. – P. 242–5. Doi: 10.1038/nature21080
Review
For citations:
Zlatnik E.Yu., Sagakyants A.B., Shatova O.P., Zabolotneva A.A., Appolonova S.A., Moskaleva N.E., Meshkov I.O., Rumyantsev S.A., Shestopalov A.V. Tryptophan metabolites in serum and feces of patients with non-small cell lung cancer. Yakut Medical Journal. 2021;(4):94-97. https://doi.org/10.25789/YMJ.2021.76.22
Views:
21
Email this article 